Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Clinical trial NCT06214793 · SUSPENDED
Trial details
- NCT number
- NCT06214793
- Sponsor
- Megan Kruse, MD
- Status
- SUSPENDED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-10-01
- Primary completion
- 2030-01-01
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.